{"id":26049,"date":"2026-09-18T15:25:07","date_gmt":"2026-09-18T15:25:07","guid":{"rendered":"https:\/\/thestrategystory.com\/blog\/?p=26049"},"modified":"2026-09-18T15:32:20","modified_gmt":"2026-09-18T15:32:20","slug":"johnson-johnson-business-model-2026-how-does-jj-make-money","status":"publish","type":"post","link":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/","title":{"rendered":"Johnson & Johnson Business Model 2026: How Does J&J Make Money?"},"content":{"rendered":"\n

Johnson & Johnson is a global healthcare company built around two complementary businesses: Innovative Medicine and MedTech. Following the separation of its former consumer health business, the company is focused on prescription medicines and medical technologies that address complex diseases and clinical procedures. Its business model combines scientific research, intellectual property, regulatory expertise, global commercial infrastructure, manufacturing and acquisitions to create products that can command value because they improve patient outcomes or enable healthcare professionals to diagnose and treat disease.<\/p>\n\n\n\n

In fiscal 2025, Johnson & Johnson generated worldwide sales of $94.2 billion, up 6.0% from 2024. Innovative Medicine produced $60.4 billion of sales and MedTech produced $33.8 billion. The company spent $14.7 billion on research and development, equal to 15.6% of sales. These numbers illustrate the central economics of J&J: invest heavily in science and technology, obtain regulatory approval, build clinical adoption, protect innovations through intellectual property where possible, and monetize them through global healthcare markets.<\/p>\n\n\n\n

Johnson & Johnson Business Strategy 2026<\/a><\/p>\n\n\n\n

Industry Background & Problem<\/h2>\n\n\n\n

Healthcare markets exist because patients and health systems face persistent needs across cancer, immune-mediated diseases, neurological disorders, cardiovascular disease, surgery, vision and other areas. Solving these problems is difficult. New medicines can require years of discovery, clinical development and regulatory review, while medical devices must demonstrate safety, effectiveness, reliability and clinical value. Failure rates can be high and the investment required before commercialization can be substantial.<\/p>\n\n\n\n

The customer is also not always the same as the user or payer. A physician may prescribe a medicine, a hospital may purchase a device, a patient receives the treatment, and an insurer or government program may fund much of the cost. J&J therefore operates within a complex ecosystem of clinicians, hospitals, distributors, regulators, private insurers and public healthcare programs. Reimbursement decisions and pricing policies can materially affect commercial outcomes.<\/p>\n\n\n\n

Once a successful healthcare product reaches the market, it can still face intense competition. Pharmaceuticals eventually encounter competing therapies, generics or biosimilars, while MedTech products compete through clinical performance, innovation, physician preference, service and economics. J&J must therefore continually replenish its portfolio rather than depend indefinitely on existing products.<\/p>\n\n\n\n

Johnson & Johnson SWOT Analysis 2026<\/a><\/p>\n\n\n\n

How Johnson & Johnson Solves the Problem<\/h2>\n\n\n\n

J&J’s model starts with research and development. The company invests in discovering, testing and developing new products, improving existing products and generating evidence required for regulatory approval and clinical use. In 2025, Innovative Medicine R&D was $11.8 billion, or 19.6% of segment sales, while MedTech R&D was $2.8 billion, or 8.4% of segment sales.<\/p>\n\n\n\n

Internal research is complemented by acquisitions, licensing and collaborations. This allows J&J to obtain technologies or products developed outside the company and combine them with its development, regulatory and commercial capabilities. Collaborative arrangements can include upfront payments, milestones, royalties, development cost sharing and profit sharing. Acquisitions can add commercial products as well as pipeline assets and technology platforms.<\/p>\n\n\n\n

After approval, J&J uses global sales, marketing and distribution capabilities to reach healthcare professionals and institutions. In medicines, commercial success depends on clinical differentiation, inclusion in treatment pathways, reimbursement and access. In MedTech, it can also depend on procedural adoption, physician training, installed systems, complementary instruments and continued product innovation.<\/p>\n\n\n\n

Johnson & Johnson PESTEL Analysis 2026<\/a><\/p>\n\n\n\n

Johnson & Johnson Business Model<\/h2>\n\n\n\n

At its core, Johnson & Johnson operates a portfolio model. It allocates capital and R&D across multiple therapeutic areas and medical technology categories rather than relying on a single product. The two segments have different economics but share important capabilities: science, clinical evidence, regulation, manufacturing quality, intellectual property and relationships across healthcare systems.<\/p>\n\n\n\n

Innovative Medicine<\/h3>\n\n\n\n

Innovative Medicine develops prescription therapies across Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism. The segment generated $60.4 billion in 2025 sales, up 6.0%. Its economics are driven by products that can achieve significant sales during periods of clinical differentiation and intellectual-property protection, balanced against substantial R&D expense and eventual competitive pressure.<\/p>\n\n\n\n

Oncology was particularly important in 2025, with sales of $25.4 billion. DARZALEX generated $14.35 billion, while CARVYKTI generated $1.89 billion. J&J also markets therapies such as ERLEADA, RYBREVANT, TECVAYLI, TALVEY and other products across cancer categories. A broad oncology franchise allows the company to participate across different diseases, mechanisms and treatment settings.<\/p>\n\n\n\n

The portfolio approach matters because mature medicines can decline when exclusivity weakens. The FY2025 report highlights the impact of biosimilar competition on STELARA. J&J therefore needs growth products and pipeline launches to offset erosion in older franchises. New indications can also extend the commercial opportunity of successful medicines by expanding the eligible patient population.<\/p>\n\n\n\n

MedTech<\/h3>\n\n\n\n

MedTech generated $33.8 billion of 2025 sales. It serves healthcare professionals through products used in surgery, orthopaedics, cardiovascular procedures and vision care. Unlike a prescription medicine that is primarily monetized through units of therapy, MedTech can combine capital equipment, instruments, implants, disposables, procedure-related products and service relationships.<\/p>\n\n\n\n

J&J’s MedTech strategy increasingly emphasizes higher-growth markets and differentiated technologies. Shockwave, acquired in 2024, generated $1.15 billion of worldwide sales in 2025. Vision generated $5.47 billion. Acquisitions can accelerate entry into attractive clinical categories where J&J believes its global infrastructure can support broader commercialization.<\/p>\n\n\n\n

Clinical workflow can strengthen MedTech relationships. Surgeons and hospitals often require product training, procedural familiarity and dependable supply. This means commercial capabilities extend beyond advertising: education, technical support, evidence generation and integration into clinical practice can influence adoption.<\/p>\n\n\n\n

How Does Johnson & Johnson Make Money?<\/h2>\n\n\n\n

J&J primarily makes money by selling pharmaceutical products and medical technologies to customers worldwide. In 2025, consolidated sales were approximately $94.2 billion. Innovative Medicine contributed $60.4 billion, or roughly 64% of total sales, while MedTech contributed $33.8 billion, or about 36%.<\/p>\n\n\n\n

Geographically, the United States is the company’s largest market. U.S. sales were $53.75 billion in 2025. Europe generated $21.54 billion, while the remainder came from other international markets. This geographic mix gives J&J substantial exposure to the U.S. healthcare system while maintaining a broad international commercial base.<\/p>\n\n\n\n

1. Sales of prescription medicines<\/h3>\n\n\n\n

The largest revenue engine is Innovative Medicine. J&J sells therapies for serious diseases and earns revenue when products are purchased through healthcare channels. Product economics depend on treatment volumes, pricing, rebates, reimbursement, market access and competitive positioning. Government programs, private insurers and managed-care organizations can materially influence net realized revenue through reimbursement and rebates.<\/p>\n\n\n\n

Successful medicines can become very large franchises. DARZALEX alone generated more than $14 billion in 2025 sales. At the same time, concentration in major products creates lifecycle risk, which is why the company invests across multiple therapeutic areas and development programs.<\/p>\n\n\n\n

2. Sales of medical devices and technologies<\/h3>\n\n\n\n

MedTech earns revenue from products used in clinical procedures and patient care. Categories include surgery, orthopaedics, cardiovascular intervention and vision. Revenue can be supported by recurring procedure volumes because many products are consumed or implanted during treatment. Capital equipment and enabling technologies can also create ecosystems around which instruments and procedure-specific products are used.<\/p>\n\n\n\n

The segment’s $33.8 billion sales base gives J&J diversification from pharmaceutical patent cycles, although MedTech faces its own pressures from hospital budgets, competition, pricing and rapid product innovation.<\/p>\n\n\n\n

3. New indications and lifecycle expansion<\/h3>\n\n\n\n

A medicine’s commercial opportunity can grow after its original launch if clinical trials support additional indications, patient groups or treatment settings. This allows J&J to leverage an existing molecule, manufacturing base and commercial organization while expanding addressable demand. Lifecycle management is therefore an important component of pharmaceutical economics.<\/p>\n\n\n\n

4. Acquisitions and externally sourced innovation<\/h3>\n\n\n\n

J&J also expands its revenue base by acquiring companies and rights to technologies. Recent portfolio additions reflected in the FY2025 report include CAPLYTA through the Intra-Cellular acquisition and Shockwave in MedTech. Acquisitions can provide immediate revenue, pipeline assets or technology platforms, while J&J contributes global development and commercialization capabilities.<\/p>\n\n\n\n

5. Collaboration economics<\/h3>\n\n\n\n

Some products are developed or commercialized through collaborations. Depending on the arrangement, J&J can receive product sales and profit-share payments or make and receive royalties, milestones and development payments. Profit-share payments included in sales were less than 2% of total revenue in 2025, so collaborations supplement rather than dominate the revenue model.<\/p>\n\n\n\n

Cost Structure and Economics<\/h2>\n\n\n\n

The defining cost of J&J’s model is innovation. Total R&D expense was $14.67 billion in 2025. This spending funds discovery, clinical trials, product improvement, regulatory work and externally sourced development programs. Many projects will never become major commercial products, so the economics of successful innovations must compensate for portfolio-wide development risk.<\/p>\n\n\n\n

Selling, marketing and administrative costs are also significant because healthcare products require global commercial organizations, market-access capabilities and corporate infrastructure. Manufacturing must meet demanding quality standards, while regulatory and compliance activities are embedded throughout the product lifecycle.<\/p>\n\n\n\n

J&J’s scale can create operating leverage. A successful product can use established regulatory, manufacturing and commercial infrastructure across many markets. Similarly, an acquired technology can potentially be accelerated through an existing global organization. This is one reason scale and portfolio breadth can be valuable in healthcare.<\/p>\n\n\n\n

Competitive Advantages and Value Proposition<\/h2>\n\n\n\n

J&J’s first major advantage is scientific breadth. It can fund research across multiple therapeutic and technology platforms and absorb the uncertainty inherent in healthcare innovation. Its second advantage is global commercialization: approved products can be launched through established relationships and market-access capabilities across major healthcare systems.<\/p>\n\n\n\n

A third advantage is portfolio diversification. Innovative Medicine and MedTech face different product cycles, customer dynamics and competitive structures. Within each segment, J&J also operates across multiple categories. Diversification does not eliminate product-specific risk, but it reduces dependence on a single technology or disease area.<\/p>\n\n\n\n

Fourth, acquisitions and collaborations give J&J access to external innovation. The company does not need every important technology to originate internally. Its capital base and development infrastructure allow it to buy, license or partner for assets that fit strategic priorities.<\/p>\n\n\n\n

Finally, healthcare creates meaningful barriers to entry. Regulatory approvals, clinical evidence, manufacturing quality, physician trust, reimbursement access and intellectual property can make successful franchises difficult to replicate quickly. J&J’s long-established capabilities across these areas support its ability to commercialize innovation at scale.<\/p>\n\n\n\n

Future Outlook<\/h2>\n\n\n\n

The future of J&J’s business model depends on replacing mature products with new growth platforms while continuing to strengthen MedTech. The 2025 results show this transition in action: strong oncology growth and acquired businesses such as CAPLYTA and Shockwave supported growth while STELARA faced biosimilar pressure.<\/p>\n\n\n\n

The company must continue converting its R&D spending into approved products, new indications and clinically differentiated technologies. Acquisitions will remain another mechanism for accessing innovation, but returns depend on integration, development success and the price paid for assets.<\/p>\n\n\n\n

Pricing and reimbursement will remain central constraints. The FY2025 report notes government-established pricing under the U.S. Inflation Reduction Act beginning in 2026 for certain products, alongside broader pressure from government and private payers. The strength of J&J’s model will therefore increasingly depend on demonstrating meaningful clinical value while sustaining a pipeline capable of offsetting price and exclusivity pressures.<\/p>\n\n\n\n

Overall, Johnson & Johnson’s business model is a reinvestment cycle: generate cash from a diversified portfolio of medicines and medical technologies, reinvest heavily in internal and external innovation, use clinical and regulatory capabilities to bring new products to market, and commercialize them through a global healthcare network. Its long-term economics depend less on any single year’s products than on continuously renewing that cycle.<\/p>\n\n\n\n

Source:<\/strong> Johnson & Johnson, FY2025 Annual Report \/ Form 10-K<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Explore Johnson & Johnson’s business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.<\/p>\n","protected":false},"author":1,"featured_media":26006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_focuskw":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[166],"tags":[],"class_list":{"0":"post-26049","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-model"},"yoast_head":"\nJohnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story<\/title>\n<meta name=\"description\" content=\"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story\" \/>\n<meta property=\"og:description\" content=\"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/\" \/>\n<meta property=\"og:site_name\" content=\"The Strategy Story\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-18T15:25:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-18T15:32:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/fe-ngo-bvx3G7RkOts-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/\",\"url\":\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/\",\"name\":\"Johnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story\",\"isPartOf\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\"},\"datePublished\":\"2026-09-18T15:25:07+00:00\",\"dateModified\":\"2026-09-18T15:32:20+00:00\",\"author\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\"},\"description\":\"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.\",\"breadcrumb\":{\"@id\":\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thestrategystory.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson Business Model 2026: How Does J&J Make Money?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#website\",\"url\":\"https:\/\/thestrategystory.com\/blog\/\",\"name\":\"The Strategy Story\",\"description\":\"Simplifying Business Strategies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/thestrategystory.com\/blog\"],\"url\":\"https:\/\/thestrategystory.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story","description":"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story","og_description":"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.","og_url":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/","og_site_name":"The Strategy Story","article_published_time":"2026-09-18T15:25:07+00:00","article_modified_time":"2026-09-18T15:32:20+00:00","og_image":[{"width":640,"height":427,"url":"http:\/\/thestrategystory.com\/blog\/wp-content\/uploads\/2026\/09\/fe-ngo-bvx3G7RkOts-unsplash.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/","url":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/","name":"Johnson & Johnson Business Model 2026: How Does J&J Make Money? - The Strategy Story","isPartOf":{"@id":"https:\/\/thestrategystory.com\/blog\/#website"},"datePublished":"2026-09-18T15:25:07+00:00","dateModified":"2026-09-18T15:32:20+00:00","author":{"@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972"},"description":"Explore Johnson & Johnson's business model in 2026 and how J&J makes money from Innovative Medicine and MedTech based on its FY2025 Annual Report.","breadcrumb":{"@id":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thestrategystory.com\/blog\/johnson-johnson-business-model-2026-how-does-jj-make-money\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thestrategystory.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson Business Model 2026: How Does J&J Make Money?"}]},{"@type":"WebSite","@id":"https:\/\/thestrategystory.com\/blog\/#website","url":"https:\/\/thestrategystory.com\/blog\/","name":"The Strategy Story","description":"Simplifying Business Strategies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thestrategystory.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/2f78fc259746b58da95619cc4c1a7972","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thestrategystory.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/12ad6ed4e2acceb2ca63d603c4f581010634a4b2ec37d408ef885f33d01bac54?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/thestrategystory.com\/blog"],"url":"https:\/\/thestrategystory.com\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/comments?post=26049"}],"version-history":[{"count":2,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26049\/revisions"}],"predecessor-version":[{"id":26058,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/posts\/26049\/revisions\/26058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media\/26006"}],"wp:attachment":[{"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/media?parent=26049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/categories?post=26049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thestrategystory.com\/blog\/wp-json\/wp\/v2\/tags?post=26049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}